Table 2.

Summary of AEs in Studies 1 (Part 1) and 2 in patients receiving volasertib and azacitidine

n (%)	Study 1 Part 1 (n = 13)	Study 2 (n = 5)
Any AE	12 (92)	5 (100)
DRAE	12 (92)	5 (100)
AE leading to dose reduction of volasertib	3 (23)	1 (20)
AE leading to dose reduction of azacitidine	0	2 (40)
AE leading to discontinuation of trial medication	6 (46)	0
SAE	8 (62)	2 (40)
DLT	2 (15)	2 (40)
Worst CTCAE grade
Grade 1	0	0
Grade 2	0	0
Grade 3	2 (15)	0
Grade 4	10 (77)	5 (100)
Grade 5	0	0

AE adverse event, CTCAE Common Terminology Criteria for Adverse Events, DLT dose-limiting toxicity, DRAE drug-related adverse event, SAE serious adverse event